Literature DB >> 21285412

Mitochondrial membrane potential is required for MAVS-mediated antiviral signaling.

Takumi Koshiba1, Kai Yasukawa, Yusuke Yanagi, Shun-ichiro Kawabata.   

Abstract

Mitochondria, dynamic organelles that undergo cycles of fusion and fission, are the powerhouses of eukaryotic cells and are also involved in cellular innate antiviral immunity in mammals. Mitochondrial antiviral immunity depends on activation of the cytoplasmic retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) signaling pathway and the participation of a mitochondrial outer membrane adaptor protein called MAVS (mitochondrial antiviral signaling). We found that cells that lack the ability to undergo mitochondrial fusion as a result of targeted deletion of both mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) exhibited impaired induction of interferons and proinflammatory cytokines in response to viral infection, resulting in increased viral replication. In contrast, cells with null mutations in either Mfn1 or Mfn2 retained their RLR-induced antiviral responses. We also found that a reduced mitochondrial membrane potential (ΔΨ(m)) correlated with the reduced antiviral response. The dissipation in ΔΨ(m) did not affect the activation of the transcription factor interferon regulatory factor 3 downstream of MAVS, which suggests that ΔΨ(m) and MAVS are coupled at the same stage in the RLR signaling pathway. Our results provide evidence that the physiological function of mitochondria plays a key role in innate antiviral immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21285412     DOI: 10.1126/scisignal.2001147

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  109 in total

1.  Mitochondria and antiviral innate immunity.

Authors:  Takumi Koshiba; Nasir Bashiruddin; Shunichiro Kawabata
Journal:  Int J Biochem Mol Biol       Date:  2011-08-15

2.  Listeria infection modulates mitochondrial dynamics.

Authors:  Fabrizia Stavru; Pascale Cossart
Journal:  Commun Integr Biol       Date:  2011-05

3.  The microRNAs miR-302b and miR-372 regulate mitochondrial metabolism via the SLC25A12 transporter, which controls MAVS-mediated antiviral innate immunity.

Authors:  Kai Yasukawa; Daisuke Kinoshita; Keisuke Yaku; Takashi Nakagawa; Takumi Koshiba
Journal:  J Biol Chem       Date:  2019-11-25       Impact factor: 5.157

4.  The RNA- and TRIM25-Binding Domains of Influenza Virus NS1 Protein Are Essential for Suppression of NLRP3 Inflammasome-Mediated Interleukin-1β Secretion.

Authors:  Miyu Moriyama; I-Yin Chen; Atsushi Kawaguchi; Takumi Koshiba; Kyosuke Nagata; Haruko Takeyama; Hideki Hasegawa; Takeshi Ichinohe
Journal:  J Virol       Date:  2016-03-28       Impact factor: 5.103

Review 5.  Mechanisms of MAVS regulation at the mitochondrial membrane.

Authors:  Jana L Jacobs; Carolyn B Coyne
Journal:  J Mol Biol       Date:  2013-10-09       Impact factor: 5.469

6.  Regulation of mitochondrial antiviral signaling (MAVS) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (MAM) protein Gp78.

Authors:  Jana L Jacobs; Jianzhong Zhu; Saumendra N Sarkar; Carolyn B Coyne
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

7.  Mitochondrial protein mitofusin 2 is required for NLRP3 inflammasome activation after RNA virus infection.

Authors:  Takeshi Ichinohe; Tatsuya Yamazaki; Takumi Koshiba; Yusuke Yanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-14       Impact factor: 11.205

Review 8.  Mitochondria in innate immunity.

Authors:  Damien Arnoult; Fraser Soares; Ivan Tattoli; Stephen E Girardin
Journal:  EMBO Rep       Date:  2011-09-01       Impact factor: 8.807

9.  Molecular characterization of a peritrophic membrane protein from the silkworm, Bombyx mori.

Authors:  Xiaolong Hu; Lin Chen; Rui Yang; Xingwei Xiang; Xiaofeng Wu
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 10.  Intracellular pathogen detection by RIG-I-like receptors.

Authors:  Evelyn Dixit; Jonathan C Kagan
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.